Q-omics provides the consensus-scored VDAC2P4 profile across patient tissues and cancer cell-line models. VDAC2P4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, VDAC2P4 is differentially expressed in 6, with the highest sampling consensus in LUSC. Additionally, VDAC2P4 RNA expression shows 11,148 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight OV, LUSC, and THYM as cancer lineages where VDAC2P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VDAC2P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VDAC2P4 survival associations across molecular data types. VDAC2P4 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VDAC2P4 RNA expression–survival associations across cancer types. High VDAC2P4 expression shows unfavorable associations in OV, THCA, KIRP, UCEC and COAD, but favorable associations in BRCA. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for VDAC2P4 RNA expression.
This table summarizes VDAC2P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for VDAC2P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VDAC2P4 shows lower tumor expression in UCEC and BRCA and higher tumor expression in LUSC, BLCA, LUAD and STAD. The LUSC box plot shows higher VDAC2P4 RNA expression in tumor versus normal tissue (log2 FC = +0.068, t-test p = .001).
This table shows molecular features associated with VDAC2P4 in patient tissues and cancer cell lines. In patient samples, VDAC2P4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
